# GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLC

> **NCT03417882** · PHASE2 · TERMINATED · sponsor: **BrightPath Biotherapeutics** · enrollment: 20 (actual)

## Conditions studied

- Metastatic NSCLC

## Interventions

- **BIOLOGICAL:** GRN-1201 + Pembrolizumab

## Key facts

- **NCT ID:** NCT03417882
- **Lead sponsor:** BrightPath Biotherapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-01-03
- **Primary completion:** 2022-12-05
- **Final completion:** 2022-12-05
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** Recruitment rate too slow
- **Last updated:** 2023-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03417882

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03417882, "GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLC". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03417882. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*